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Abstract
Introduction: The efficacy of adalimumab, a fully human anti-tumor necrosis factor a recombinant antibody, has
dramatically improved the quality of life of patients with rheumatoid and psoriatic arthritis and Crohn’s disease.
Because it is fully human, one should not expect immune reactions to this molecule. Adverse reactions to
adalimumab are limited mainly to injection site reactions and are very common. Immediate systemic reactions are
rarely reported.
Case presentation: We report the case of a 61-year-old Caucasian woman who was treated with adalimumab for
spondylarthritis and developed injection site reactions after the sixth dose. After a two-month suspension, she
recommenced therapy and experienced two systemic reactions. The first occurred after one hour with itching of
the palms and soles and angioedema of the tongue and lips. Thirty minutes after the next dose the patient had
itching of the palms and soles with diffusion to her whole body, angioedema of the lips, dizziness and visual
disturbances. A skin-prick test and intra-dermal tests with adalimumab gave strong positive results at the
immediate reading. However, serum-specific immunoglobulin E (IgE) to adalimumab were not detectable by using
Phadia solid phase, especially harvested for this case, in collaboration with our Immunology and Allergy Laboratory
Unit. Her total IgE concentration was 6.4 kU/L.
Conclusion: We describe what is, to the best of our knowledge, the first reported case of immediate systemic
reaction to adalimumab studied with a skin test giving positive results and a serum-specific IgE assay giving
negative results. The mechanism of the reaction must be immunologic but not IgE-mediated.
Introduction
Adalimumab (Humira; Abbott Laboratories, Abbott
Park, IL, USA) is a fully human recombinant immuno-
globulin G1 (IgG1) monoclonal antibody with specificity
for human tumor necrosis factor a (TNF-a). Adalimu-
mab binds to soluble and membrane-bound TNF-a,
leading to the blockade of activity of TNF. Apoptosis of
cells with membrane-bound TNF occurs. Adalimumab
was initially approved for the treatment of rheumatoid
arthritis. It was subsequently approved for treatment of
psoriatic arthritis, ankylosing spondylitis, juvenile idio-
pathic arthritis, plaque psoriasis, Crohn’s disease and
uveitis. The recommended dosage for adults with spon-
dylarthritis is a subcutaneous dose of 40 mg every other
week.
The most frequent adverse reactions to adalimumab
are injection site reactions. They occur in 6.6% to 15.3%
of the patients treated [1-3]. These reactions appear
w i t h i no n et o2 4h o u r sa tt h es i t eo fs u b c u t a n e o u s
administration and consist of erythema, edema and itch-
ing. They peak at 48 hours and last for three to five
days. Usually, they occur in the first to second month of
therapy and fade over time. The adverse reactions rarely
require cessation of treatment, although they are very
troublesome.
Immediate systemic reactions to adalimumab have
been reported in the literatu r eo n l yi nt h ep a s tt h r e e
years by six authors [4-9]. Only Rodrìguez-Jiménez et al.
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a desensitization protocol was applied with success.
However, no serologic study has been performed with
the aim of ascertaining whether the reaction was IgE-
mediated.
Here we describe the first case of an immediate sys-
temic adverse reaction to adalimumab with positive skin
tests and a serum-specific IgE assay giving negative
results.
Case presentation
We describe the case of a 61-year-old Italian Caucasian
woman who did not smoke or drink. Her medical his-
tory included hypertension and hypothyroidism after
undergoing surgery for thyroid nodulosis, for which she
was treated with valsartan, levothyroxine, atenolol and
chlorthalidone.
The patient was referred to our Outpatient Clinic for
Biological Therapy in the Hospital San Giovanni di Dio
in Florence, Italy. In the weeks before referral, her
symptoms had worsened, with the appearance of back
pain and progressive limitation of mobility. Her history
included repeated flares of sciatica, talalgia and trochan-
teritis. Her modified Schober test result was 15 cm to
18 cm.
An X-ray and a magnetic resonance imaging scan
showed sacroiliitis. A diagnosis of spondylarthritis was
made. The patient was started on therapy with sulfasala-
zine 2 g/day and deflazacort 7.5 mg/day for three months,
without improvement of her symptoms. In September
2007, because of elevated scores (>30) on both the Bath
Ankylosing Spondylitis Functional Index (BASFI) and the
Bath Ankylosing Spondylitis Disease Activity Index (BAS-
DAI) scales, the patient was started on biological therapy
with adalimumab 40 mg every other week.
After the sixth dose of adalimumab, an injection site
reaction occurred after 12 hours, with erythema, edema
and itching over a zone 5 cm to 6 cm in diameter. The
reaction peaked at 24 to 48 hours and lasted three to
four days. Prophylaxis with oral anti-histamines had lit-
tle efficacy. The clinical efficacy of the drug at that time
was satisfactory (BASFI and BASDAI scores both less
than 10). We performed prick, intra-dermal and patch
tests following the procedure previously described [10].
A commercial preparation of Humira was used which
contains, in 0.8 mL of distilled water, adalimumab 40
mg, which is a concentration of 50 mg/mL; mannitol,
9.6 mg; and polysorbate 80, 0.8 mg. For the prick and
patch test and for the intra-dermal test with late read-
ing, we used the undiluted drug (50 mg/mL). For the
intra-dermal test at immediate reading, we used a con-
centration of 5 mg/mL. These concentrations proved to
be non-irritating in 10 control subjects never treated
with adalimumab [11].
For the prick test, a reading was taken after 20 min-
utes; for the intra-dermal test, readings were taken after
15 minutes and 24 hours; and for the patch test, read-
ings were taken after 48 and 72 hours. Prick and intra-
dermal tests with adalimumab showed negative results
at the immediate reading; however, after 24 hours, an
itchy, red papule 7 mm in diameter, surrounded by an
erythema of 15 mm, occurred at the site of the intra-
dermal test and lasted five days. The patch test with the
undiluted drug was negative, as was an intra-dermal test
with mannitol (18 mg/mL).
Adalimumab was withheld for two months. In this
period, she received leflunomide. The first two doses
after the pause yielded an injection site reaction as pre-
viously. After the third dose, the patient experienced,
after one hour, a systemic reaction that manifested as
itching of the palms and soles and angioedema of the
tongue and lips. After the following dose, after 30 min-
utes, a generalized itching occurred, with lip angioe-
dema, dizziness and visual disturbances. Her symptoms
resolved with the administration of intravenous corticos-
teroids and oral anti-histamine, within one hour in the
first case and within two hours in the second case. She
also reported decreased efficacy after resuming treat-
ment with the drug. It should also be noted that she
h a ds t o p p e do r a lc o r t i c o s t e r o i d sa tt h a tt i m e ,b u th e r
BASFI and BASDAI values were both >30.
We repeated the skin tests after the systemic reac-
tions, with strong positive results at the immediate read-
ing: The skin-prick test yielded a wheal 6 mm in
diameter and a flare of 15 mm, and the intra-dermal
test was positive with 5 mm of wheal and 6 mm of flare
until the dilution of 0.005 mg/mL, that is, diluted
10,000-fold. The intra-dermal test was negative at the
late reading.
An ImmunoCAP, especially harvested by Phadia,
Uppsala, Sweden in collaboration with our Laboratory
of Immunology and Allergy, was used to assay serum-
specific IgE to adalimumab. A commercial Phadia
ImmunoCAP was used for the assay of total IgE and
specific IgE to common inhalant allergens (Phadiatop).
In vitro tests were not able to demonstrate serum-
specific IgE to adalimumab by means of Phadia Immuno-
CAP: The result was 0.01 kUA/L. Total IgE was 6.4 kU/
L. An atopic status was excluded by history and also by a
negative Phadiatop.
Discussion
We previously described, for the first time, an allergolo-
gic study of two patients with injection site reactions to
adalimumab. Intra-dermal skin tests with adalimumab
were positive at the late reading (24 hours), and patch
tests were negative [11]. Up to the present time, we
have studied three more patients: two of them showed a
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minutes), and one had a positive intra-dermal test at
both immediate and late readings. Only one other study
exists of two patients with injection site reactions who
showed positive intra-dermal tests at the immediate
reading and leukocyte histamine release with adalimu-
mab [12]. However, for the intra-dermal test, Paltiel et
al. [12] used the non-diluted drug at a concentration of
50 mg/mL and tested this concentration in only one
control patient. In our experience, the concentration of
50 mg/mL was positive in one of four never-treated
control subjects; then, for the intra-dermal test, we used
a concentration of 5 mg/mL, which was not irritating in
10 never-treated control subjects.
For the skin prick test, the undiluted drug (50 mg/mL)
was not irritating [11]. Adverse reactions to biologic
agents have been categorized into five types [13,14].
Adverse reactions of type b, that is, hypersensitivity
reactions, are mediated by an immune mechanism,
mainly type I (specific IgE), type III (specific IgG) or
type IV (lymphocytes) following the Gell and Coombs
classifications.
The immunologic mechanism underlying the systemic
reactions of our patient seems to be mediated by specific
I g E .T h ep r e s e n c eo fs p e c i f i cI g Em u s tb es u s p e c t e dn o t
only because of the types of symptoms (itching, angioe-
dema, dizziness and possible hypotension, as indicated by
the visual disturbances, and their occurrence within one
hour of administration) but also because the skin tests at
immediate reading were strongly positive, as was the prick
test, which is less sensitive than the intra-dermal test. The
other four patients who had injection site reactions to ada-
limumab, that is, a less severe reaction, showed positive
intra-dermal tests but negative skin prick tests. This would
indicate a lower level of specific antibodies.
However, we could not demonstrate the presence of
serum-specific IgE in any of these patients, even in
those with a positive intra-dermal test at the immediate
reading. We also excluded the responsibility of excipi-
ents, because the skin test with mannitol was negative.
These results suggest that another antibody could be
responsible for both the adverse reactions and the posi-
tive skin tests.
Non-IgE-mediated anaphylaxis has been described in
mice, involving specific IgG, FcgRIII, macrophages, and
PAF - platelet activating factor - in cases of repeated expo-
sure to large quantities of antigen [15]. It could be specu-
lated that a similar mechanism was underlying the
reactions of our patient. With the aim of ascertaining
whether mastocytes are involved in these reactions, it
would be useful to assay the serum tryptase in the acute
phase of the reaction. In our patient, it was not possible,
because the reaction occurred while the patient was at
home.
Conclusion
We describe what is, to the best of our knowledge, the
first case of an immediate systemic reaction to adalimu-
mab with positive skin tests and negative research into
serum-specific IgE, despite a comprehensive serologic
study. The finding of positive skin tests suggests that an
immunologic mechanism is responsible for this adverse
reaction; however, serum-specific IgE to adalimumab
could not be demonstrated by means of Phadia Immu-
noCAP. Therefore, the exact nature of this immunologic
mechanism and the antibody responsible for it remain
to be elucidated.
The clinical consequences of this finding are limited,
because the cases of adverse systemic reactions to adali-
mumab are rare. However, the conceptual implications
of this case are highly relevant, because we demon-
strated an adverse immune-mediated reaction to a fully
human recombinant biologic response modifier, not
only in this case but also in some cases of injection site
reactions to adalimumab.
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